Literature DB >> 23449690

Macronutrients during pregnancy and life-threatening respiratory syncytial virus infections in children.

F Martín Ferolla1, Diego R Hijano, Patricio L Acosta, Andrea Rodríguez, Karina Dueñas, Andrea Sancilio, Edgar Barboza, Adriana Caría, Guadalupe Fernández Gago, Rodrigo Egües Almeida, Laura Castro, Cecilia Pozzolo, María V Martínez, Luciano Alva Grimaldi, Beatriz Rebec, Mariel Calvo, Julieta Henrichsen, Celina Nocito, Mariela González, Guillermo Barbero, Juan Ves Losada, Mauricio T Caballero, Valeria Zurankovas, Mirta Raggio, Graciela Schavlovsky, Alicia Kobylarz, Vera Wimmenauer, Jimena Bugna, John V Williams, Gustavo Sastre, Edgardo Flamenco, Alberto Rodríguez Pérez, Fernando Ferrero, Romina Libster, Carlos G Grijalva, Fernando P Polack.   

Abstract

RATIONALE: Respiratory syncytial virus (RSV) is an important cause of hospitalization and death in infants worldwide. Most RSV deaths occur in developing countries, where burden and risk factors for life-threatening illness are unclear.
OBJECTIVES: We defined the burden of life-threatening (O(2) saturation [O(2) sat] ≤ 87%) and fatal RSV infection, and characterized risk factors for life-threatening disease in hospitalized children. Special emphasis was placed on studying the impact of dietary habits during pregnancy. We hypothesized that dietary preferences, differing from those of our remote ancestors, would negatively impact children's pulmonary health. For instance, a diet rich in carbohydrates is a signature of recent millennia and typical of low-income populations, heavily burdened by life-threatening RSV disease.
METHODS: Prospective study in a catchment population of 56,560 children under 2 years of age during the RSV season in Argentina. All children with respiratory signs and O(2) sat less than 93% on admission were included.
MEASUREMENTS AND MAIN RESULTS: Among 1,293 children with respiratory infections, 797(61.6%) were infected with RSV: 106 of these had life-threatening disease; 1.9 per 1,000 children (95% confidence interval [CI], 1.5-2.2/1,000) under 24 months. A total of 22 hospitalized children died (9 RSV(+)), 26 died at home due to acute respiratory infection (14 attributed to RSV); all were under 12 months old. The annual attributable mortality rate for RSV was 0.7 per 1,000 infants (95% CI, 0.4-1.1/1,000). Life-threatening disease was dose-dependently associated with carbohydrate ingestion during pregnancy (adjusted odds ratio from 3.29 [95% CI, 1.15-9.44] to 7.36 [95% CI, 2.41-22.5] versus the lowest quartile).
CONCLUSIONS: Life-threatening and fatal RSV infections are a heavy burden on infants in the developing world. Diets rich in carbohydrates during pregnancy are associated with these severe outcomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23449690     DOI: 10.1164/rccm.201301-0016OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  16 in total

Review 1.  Impact of pregravid obesity on maternal and fetal immunity: Fertile grounds for reprogramming.

Authors:  Suhas Sureshchandra; Nicole E Marshall; Ilhem Messaoudi
Journal:  J Leukoc Biol       Date:  2019-09-04       Impact factor: 4.962

2.  TLR4 genotype and environmental LPS mediate RSV bronchiolitis through Th2 polarization.

Authors:  Mauricio T Caballero; M Elina Serra; Patricio L Acosta; Jacqui Marzec; Luz Gibbons; Maximiliano Salim; Andrea Rodriguez; Andrea Reynaldi; Alejandro Garcia; Daniela Bado; Ursula J Buchholz; Diego R Hijano; Silvina Coviello; Dawn Newcomb; Miguel Bellabarba; Fausto M Ferolla; Romina Libster; Ada Berenstein; Susana Siniawaski; Valeria Blumetti; Marcela Echavarria; Leonardo Pinto; Andrea Lawrence; M Fabiana Ossorio; Arnoldo Grosman; Cecilia G Mateu; Carola Bayle; Alejandra Dericco; Mariana Pellegrini; Ignacio Igarza; Horacio A Repetto; Luciano Alva Grimaldi; Prathyusha Gudapati; Norberto R Polack; Fernando Althabe; Min Shi; Fernando Ferrero; Eduardo Bergel; Renato T Stein; R Stokes Peebles; Mark Boothby; Steven R Kleeberger; Fernando P Polack
Journal:  J Clin Invest       Date:  2015-01-02       Impact factor: 14.808

3.  Maternal body mass index: Relation with infant respiratory symptoms and infections.

Authors:  Ashley Rajappan; Anna Pearce; Hazel M Inskip; Janis Baird; Sarah R Crozier; Cyrus Cooper; Keith M Godfrey; Graham Roberts; Jane S A Lucas; Katharine C Pike
Journal:  Pediatr Pulmonol       Date:  2017-08-16

Review 4.  Intestinal Microbiota-A Promising Target for Antiviral Therapy?

Authors:  Mengling Yang; Yang Yang; Qingnan He; Ping Zhu; Mengqi Liu; Jiahao Xu; Mingyi Zhao
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

Review 5.  Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.

Authors:  Swapnil Subhash Bawage; Pooja Munnilal Tiwari; Shreekumar Pillai; Vida Dennis; Shree Ram Singh
Journal:  Adv Virol       Date:  2013-12-09

Review 6.  Immunity to RSV in Early-Life.

Authors:  Laura Lambert; Agnes M Sagfors; Peter J M Openshaw; Fiona J Culley
Journal:  Front Immunol       Date:  2014-09-29       Impact factor: 7.561

Review 7.  The Influence of the Microbiome on Early-Life Severe Viral Lower Respiratory Infections and Asthma-Food for Thought?

Authors:  Jason P Lynch; Md Al Amin Sikder; Bodie F Curren; Rhiannon B Werder; Jennifer Simpson; Páraic Ó Cuív; Paul G Dennis; Mark L Everard; Simon Phipps
Journal:  Front Immunol       Date:  2017-02-16       Impact factor: 7.561

Review 8.  Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis.

Authors:  Renato T Stein; Louis J Bont; Heather Zar; Fernando P Polack; Caroline Park; Ami Claxton; Gerald Borok; Yekaterina Butylkova; Colleen Wegzyn
Journal:  Pediatr Pulmonol       Date:  2016-10-14

Review 9.  Respiratory syncytial virus is an "opportunistic" killer.

Authors:  Mauricio T Caballero; Fernando P Polack
Journal:  Pediatr Pulmonol       Date:  2018-02-20

Review 10.  Current concepts and progress in RSV vaccine development.

Authors:  Aleks K Guvenel; Christopher Chiu; Peter Jm Openshaw
Journal:  Expert Rev Vaccines       Date:  2014-01-09       Impact factor: 5.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.